Friday is the deadline. Submit your 46th Annual Meeting abstract for consideration today: loom.ly/pHJW4-E

Amazing RA alert!! Ching-Hsuan Lin CEVR presents work on what information community, patient and health care stakeholders want when considering the benefit of an intervention. Spoiler alert: #1 requested outcome was the #QALY !

ISPOR #ISPORAnnual Commonwealth Fund

It was a pleasure collaborating with Jason Shafrin and Lou Garrison on this STAT First Opinion piece. What an opportunity to be together at #ISPORAnnual when it was published!

It’s the last day #ISPORAnnual and Value Flowers continue to bloom.

CEVR Bill Padula, PhD Anirban Basu No Patient Left Behind UW School of Pharmacy USC Schaeffer Center nance devlin

.@Mel_whittington presents on dynamic pricing #ISPORAnnual in good (8 a.m.) session on GCEA.

CEVR No Patient Left Behind NPC UW School of Pharmacy #heor Lotte Steuten

Come find me at poster 4012 to discuss CEVR SPEC database research on commercial coverage of Accelerated Approval drugs. And grab a copy of our Annual Specialty Drug Coverage Trend Report 2024! #ISPORAnnual #heor #hta

Great to be #ISPORAnnual with my CEVR colleagues!

Getting a lot of steps #ISPORAnnual .

Not me. Probably Anirban Basu. Or maybe Sean Sullivan.

Look forward to seeing everyone #ISPORannual in Atlanta!

A new record!

In Health Affairs Forefront today, Bob Kaplan, Joshua Salomon @jsalomon.bsky.social, Marthe Gold & I argue that QALYs or related methods are the best way to assure fair treatment of people with disabilities & chronic illnesses.

tinyurl.com/2p94uduc CEVR ICER UW School of Pharmacy Stacie Dusetzina

'Robert Kaplan Stanford Medicine, Peter Neumann CEVR, Joshua Salomon FSI Stanford, and Marthe Gold @nyamnyc explore potential harm to individuals with disabilities and chronic illnesses from proposed 'House QALY ban' in Health Affairs Forefront. tinyurl.com/mrx87uju

The CEVR Spring newsletter is out!

Featuring new research in valuing health, how payers are covering cell & gene drugs, and other issues.

tinyurl.com/42f3rny9 #heor #healtheconomics

ISPOR annual meeting is just around the corner! Excited to be presenting our research using CEVR SPEC data. Let’s connect! #isporannual #heor #marketaccess

Congratulations to the Tufts-CEVR team for another successful annual meeting!

It was wonderful to speak w/ carey goldberg this week at CEVR's annual meeting about her excellent new book on #AI in #medicine (w/ Peter Lee & Isaac Kohane.

As she noted, what we're seeing is both awe-inspiring and disturbing. #books #Bioinformatics #heor #healtheconomics

Great to speak with Barry Greene, CEO of Sage Therapeutics, today at CEVR's annual meeting and hear his views on value-based health care and innovation.
Thanks to Barry for his leadership in the field. Brian Reid Frank S. David No Patient Left Behind

Pleased to join Feng Xie & colleagues on this paper showing no systematic differences in cost effectiveness conclusions between CEAs focused on individuals ≥65 years and CEAs on those age< 65 years.
CEVR Patricia Synnott ISPORJournals

From the always intriguing Brian Reid:

Why the initial 10 medicines in Medicare drug negotiations may be just an 'amuse-bouche.'

tinyurl.com/9xhcdp92 CEVR #medicare #drugs #drugprices #IRA